COMPEL Study Finds Adding Chemotherapy to Osimertinib After Progression Enhances Progression-Free Survival in EGFR-Mutated NSCLC
In a groundbreaking development in the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) ...
